Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts. Cll is especially interested in papers describing clinical trial designs and outcome regardless of whether they met their designated endpoints or not, and particularly those shedding light on immunological mechanisms.

CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT), and Sociedad Española de Inmunologia-Grupo Española de InmunoTerapia (SEI-GEIT).

CIMT: http://www.cimt.eu/home

CCIC: http://www.immunotherapycancer.ca/

JACI: http://www.jaci.jp/eng/index.html

NIBIT: http://www.nibit.org/index.php

SEI-GEIT: http://www.inmunologia.org/grupos/home.php?UpOm5=M&Upfqym5uom=GK

CITIM: http://www.canceritim.org 94% of authors who answered a survey reported that they would definitely publish or probably publish in the journal again

Journal information

Editor-in-Chief
  • Haidong Dong
Publishing model
Hybrid (Transformative Journal). Learn about publishing Open Access with us

Journal metrics

5.442 (2019)
Impact factor
4.781 (2019)
Five year impact factor
34 days
Submission to first decision
154 days
Submission to acceptance
570,099 (2020)
Downloads

Latest articles

Journal updates

  • COVID-19 and impact on peer review

    As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times.  Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

View all updates

Subscribe

eJournal
$119.00
Note this is only the net price. Taxes will be calculated during checkout.
  • Immediate online access with complete access to all articles starting 1997
  • Downloadable in PDF format
  • Subscription expires 12/31/2021

About this journal

Electronic ISSN
1432-0851
Print ISSN
0340-7004
Abstracted and indexed in
  1. AGRICOLA
  2. BFI List
  3. BIOSIS
  4. Biological Abstracts
  5. CNKI
  6. Chemical Abstracts Service (CAS)
  7. Current Contents/ Life Sciences
  8. Dimensions
  9. EBSCO Academic Search
  10. EBSCO Biomedical Reference Collection
  11. EBSCO Discovery Service
  12. EBSCO STM Source
  13. EMBASE
  14. Elsevier Biobase
  15. Google Scholar
  16. Institute of Scientific and Technical Information of China
  17. Japanese Science and Technology Agency (JST)
  18. Journal Citation Reports/Science Edition
  19. Medline
  20. Naver
  21. Norwegian Register for Scientific Journals and Series
  22. OCLC WorldCat Discovery Service
  23. Pathway Studio
  24. ProQuest Biological Science Database
  25. ProQuest Central
  26. ProQuest Health & Medical Collection
  27. ProQuest Health Research Premium Collection
  28. ProQuest Immunology Abstracts
  29. ProQuest Medical Database
  30. ProQuest Natural Science Collection
  31. ProQuest Pharma Collection
  32. ProQuest Public Health Database
  33. ProQuest SciTech Premium Collection
  34. ProQuest-ExLibris Primo
  35. ProQuest-ExLibris Summon
  36. Reaxys
  37. SCImago
  38. SCOPUS
  39. Science Citation Index
  40. Science Citation Index Expanded (SciSearch)
  41. Semantic Scholar
  42. TD Net Discovery Service
  43. UGC-CARE List (India)
Copyright information

Rights and permissions

Springer policies

© Springer-Verlag GmbH Germany, part of Springer Nature